Gland Pharma's (NSE:GLAND, BOM:543245) attributable consolidated profit almost doubled to 3.67 billion Indian rupees in the fiscal fourth quarter from 1.87 billion rupees a year ago.
Earnings per share jumped to 22.23 rupees from 11.32 rupees over the period, according to a Friday filing to the Indian stock exchanges by the pharmaceutical company.
Revenue from operations during the quarter also increased to 17.43 billion rupees from 14.25 billion rupees a year earlier.
The company's board recommended a final dividend of 20 rupees per share for the financial year ended March 31.